Philina Lee
Board Member
Philina Lee, Ph.D., age 49, most recently served as Chief Commercial Officer at Blueprint Medicines from April 2022 to October 2025. Over more than a decade with the company, she held a series of strategic and operational leadership roles spanning the value chain — from establishing the New Product Strategy and Development function, to leading the Portfolio Strategy and Program Leadership function, and ultimately overseeing the successful launch and growth of AYVAKIT®.
Dr. Lee brings 20 years of biopharmaceutical and healthcare experience across immune and inflammatory disorders, rare diseases and oncology. She is recognized for building high-growth organizations and cultivating high-performing teams to accelerate the delivery of life-changing medicines to patients.
Earlier in her career, Dr. Lee held marketing and commercial leadership roles of increasing responsibility at Algeta, Sanofi, and Genzyme. She also served on the Board of Directors of Fusion Pharmaceuticals from 2021 to 2024, where she was a member of both the Nomination and Governance Committee and the Research and Development Committee.
Dr. Lee earned a B.S. in Biochemistry from the University of Alberta and a Ph.D. in Cell Biology from the Massachusetts Institute of Technology.